Midterm elections changed the political landscape in Washington and across the country. AAM President and CEO Chip Davis invites you to attend Access! 2019 and lend your voice to the conversations and debate in their wake. Learn more at: http://bit.ly/Access2019
Diverse Coalition Says USMCA Violates U.S. Law, Protects Drug Monopolies and Keeps Price of Medicine High, Hurting Patients and American Businesses
WASHINGTON DC (October 11, 2018) – We appreciate the efforts of the FDA, under the leadership of Commissioner Gottlieb, to lower overall drug prices by seeking to increase the number of generic drug applications on an annual basis. It is important however to recognize that in the current U.S. health care system more generic approvals does not automatically translate into more competition.
The U.S. Food and Drug Administration (FDA) plays a critical role in keeping Americans healthy. When it comes to drug approvals, the FDA’s scientists and regulators strive every day to keep pace with the most current advances in science so that patients can benefit from innovative, safe, and effective medicines.
WASHINGTON DC (September 20, 2018) – “The Congressional Budget Office (CBO) has released its score, estimating that the CREATES Act would save taxpayers $3.9 billion by accelerating the use of more affordable generic and biosimilar medicines.
In 2014, Ariel Leaty received a frightening diagnosis—acute lymphocytic leukemia. “I went through three years of chemotherapy,” Leaty, 29, of Bloomfield NJ, recalls, “followed by outpatient maintenance.”
The ordeal was grueling, but it would have been far worse, if not deadly, without generic drugs. “If I didn’t have generic prescriptions,” Leaty says, “I probably wouldn’t be here, because the brand-name drugs are expensive—sometimes over $200 a bottle.”
More than 9 out of 10 generic drug prescriptions are filled for $20 or less. Everybody who takes medicine to get or stay healthy can appreciate these savings, which allow patients and families to spend their money on other things that matters to them. Those savings, however, are now in jeopardy, thanks to a combination of factors. Here’s what you need to know.
The 10th edition of AAM’s annual generic drug savings and access report, which was released last month, is full of important data for policymakers as well as industry leaders. The report provides detailed information on savings by state, payer type, treatment area, and other factors, as well as the state of the biosimilars market. Here are 10 noteworthy takeaways from the publication.
More than 9 out of 10 generic drug prescriptions are filled for $20 or less. Everybody who takes medicine to get or stay healthy can appreciate these savings, which allow patients and families to spend their money on other things that matters to them. Those savings, however, are now in jeopardy, thanks to a combination of factors. Here’s what you need to know.
"I was diagnosed with leukemia ALL in July of 2014 and had to endure three years of chemotherapy. In the beginning of my regimen, the doctors gave me tons of pills and infusions designed to kill the cancer, which subsequently weakened my immune system and depleted my energy. For a time, I could barely walk or talk. After my intensive therapy, I immediately began outpatient maintenance, which meant taking six to 10 pills a day, in addition to daily infusions.